{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:14Z","timestamp":1792290554595,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess through systematic review and meta-analysis whether plasma exchange (PE) is associated with prognosis in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search of PubMed, MEDLINE, Embase, and CENTRAL databases from inception to 17 June 2020 was conducted. Ongoing or unpublished trials were also searched in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> and the World Health Organization trials portal. Randomised controlled trials (RCTs) comparing PE vs. non-PE in AAV patients (microscopic polyangiitis [MPA], granulomatosis with polyangiitis [GPA], or eosinophilic granulomatosis with polyangiitis [EGPA]) were included. The combined risk ratio (RR) was calculated by the random-effects model using the Mantel-Haenszel method. Heterogeneity was measured using the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic. Primary outcomes were mortality, clinical remission (CR), and adverse events (AEs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four RCTs comparing PE vs. no PE (<jats:italic>N<\/jats:italic>\u2009=\u2009827) and 1 RCT comparing PE vs. pulse steroid treatment (<jats:italic>N<\/jats:italic>\u2009=\u2009137) were included. All participants were MPA or GPA patients (no EGPA patients). PE was not associated with main primary outcomes compared with no PE (mortality RR 0.93 [95% confidence interval {CI} 0.70\u20131.24], <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u20090%; CR RR 1.02 [95% CI 0.91\u20131.15], <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u20090%; and AE RR 1.10 [95% CI 0.73\u20131.68], <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u200937%) or pulse steroid (mortality RR 0.99 [95% CI 0.71\u20131.37]; CR [the Birmingham Vasculitis Activity score] mean difference\u2009\u2212\u20090.53 [95% CI \u2212\u20091.40\u20130.34]; and AE RR 1.05 [95% CI 0.74\u20131.48]). Focusing on the early treatment phases, PE was associated with a reduction in end-stage renal disease incidence compared with both no PE (PE 1\/43 vs. no PE 10\/41; RR 0.14 [0.03\u20130.77] at 3\u2009months) and pulse steroid (PE 11\/70 vs. pulse steroid 23\/67; RR 0.46 [0.24\u20130.86] at 3\u2009months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We carried out a systematic review and meta-analysis targeting all AAV patients, including MPA, GPA, and EGPA. In AAV patients, performing PE was not associated with the risk of mortality, CR, and AE. No RCT exists evaluating the efficacy of PE for EGPA; hence, this is required in the future. The results may affect the development of guidelines for AAV and may indicate the direction of future clinical research on AAV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>UMIN <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000045239\">R000045239<\/jats:ext-link>, PROSPERO <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020182566\">CRD42020182566<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02415-z","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:02:53Z","timestamp":1610629373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-4919","authenticated-orcid":false,"given":"Yosuke","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuta","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"3","key":"2415_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5152\/eurjrheum.2015.0043","volume":"3","author":"C Pagnoux","year":"2016","unstructured":"Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2016;3(3):122\u201333.","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"2415_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7861\/clinmedicine.17-1-60","volume":"17","author":"M Yates","year":"2017","unstructured":"Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond). 2017;17(1):60\u20134.","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"2415_CR3","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2415_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","volume":"29","author":"M Harigai","year":"2019","unstructured":"Harigai M, Nagasaka K, Amano K, Bando M, Dobashi H, Kawakami T, et al. 2017 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol. 2019;29(1):20\u201330.","journal-title":"Mod Rheumatol"},{"issue":"12","key":"2415_CR5","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","volume":"53","author":"E Ntatsaki","year":"2014","unstructured":"Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2415_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2415_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2415_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","volume":"75","author":"D Geetha","year":"2020","unstructured":"Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020;75(1):124\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2415_CR9","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4550","volume":"16","author":"KE Sada","year":"2014","unstructured":"Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2415_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"10","key":"2415_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2215\/CJN.02500317","volume":"12","author":"JC Jennette","year":"2017","unstructured":"Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017;12(10):1680\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2415_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","volume":"10","author":"JC Jennette","year":"2014","unstructured":"Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463\u201373.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2415_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52\u201364.","journal-title":"Am J Pathol"},{"key":"2415_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2016.00256","volume":"7","author":"D Soderberg","year":"2016","unstructured":"Soderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. Front Immunol. 2016;7:256.","journal-title":"Front Immunol"},{"key":"2415_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","volume":"2012","author":"JL Winters","year":"2012","unstructured":"Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematol Am Soc Hematol Educ Program. 2012;2012:7\u201312.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"2415_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","volume":"23","author":"MH Mokrzycki","year":"1994","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23(6):817\u201327.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2415_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh C-A, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"2415_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.ajkd.2010.10.049","volume":"57","author":"M Walsh","year":"2011","unstructured":"Walsh M, Catapano F, Szpirt W, Thorlund K, Bruchfeld A, Guillevin L, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis. 2011;57(4):566\u201374.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2415_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/14397595.2018.1500111","volume":"29","author":"K Nagasaka","year":"2019","unstructured":"Nagasaka K, Harigai M, Hagino N, Hara A, Horita T, Hayashi T, et al. Systematic review and meta-analysis for 2017 clinical practice guidelines of the Japan research committee of the ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis. Mod Rheumatol. 2019;29(1):119\u201329.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2415_CR20","first-page":"Cd003232","volume":"1","author":"GD Walters","year":"2020","unstructured":"Walters GD, Willis NS, Cooper TE, Craig JC. Interventions for renal vasculitis in adults. Cochrane Database Syst Rev. 2020;1(1):Cd003232.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2415_CR21","first-page":"149","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice\u2013evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue. J Clin Apher. 2016;31(3):149\u2013338.","journal-title":"J Clin Apher"},{"issue":"5","key":"2415_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.transci.2017.08.010","volume":"56","author":"A Ohkubo","year":"2017","unstructured":"Ohkubo A, Okado T. Selective plasma exchange. Transfusion Apher Sci. 2017;56(5):657\u201360.","journal-title":"Transfusion Apher Sci"},{"issue":"5","key":"2415_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.transci.2017.08.009","volume":"56","author":"M Mineshima","year":"2017","unstructured":"Mineshima M. Double filtration plasmapheresis: determination of the optimal albumin concentration in the supplementation fluid. Transfusion Apher Sci. 2017;56(5):654\u20136.","journal-title":"Transfusion Apher Sci"},{"key":"2415_CR24","first-page":"234","volume":"129","author":"CM Lockwood","year":"1987","unstructured":"Lockwood CM, Savage CO, Pusey CD. Specific immunoabsorption. CIBA Found Symp. 1987;129:234\u201357.","journal-title":"CIBA Found Symp"},{"key":"2415_CR25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"7","key":"2415_CR26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2415_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh M, Casian A, Flossmann O, Westman K, H\u00f6glund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397\u2013402.","journal-title":"Kidney Int"},{"issue":"1","key":"2415_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ndt\/gfq360","volume":"26","author":"WM Szpirt","year":"2011","unstructured":"Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener\u2019s granulomatosis--a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26(1):206\u201313.","journal-title":"Nephrol Dial Transplant"},{"key":"2415_CR29","unstructured":"Nct. The Clinical Efficacy of DFPP in Patients With AAGN. 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02294344. Accessed 17 June 2020."},{"issue":"4","key":"2415_CR30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.1991.272","volume":"40","author":"CD Pusey","year":"1991","unstructured":"Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757\u201363.","journal-title":"Kidney Int"},{"issue":"1","key":"2415_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/ajkd.2002.29874","volume":"39","author":"I Zauner","year":"2002","unstructured":"Zauner I, Bach D, Braun N, Kramer BK, Funfstuck R, Helmchen U, et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2002;39(1):28\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"7952","key":"2415_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(76)91272-1","volume":"307","author":"E Cathcart","year":"1976","unstructured":"Cathcart E, Scheinberg M, Idelson B, Couser W. Beneficial effects of methylprednisolone \u201cpulse\u201d therapy in diffuse proliferative lupus nephritis. Lancet. 1976;307(7952):163\u20136.","journal-title":"Lancet"},{"issue":"6","key":"2415_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0272-6386(88)80079-9","volume":"11","author":"WG Couser","year":"1988","unstructured":"Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11(6):449\u201364.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2415_CR34","first-page":"198","volume":"148","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cevallos R, Durand-Gasselin B, Lhote F, Jarrousse B, Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris). 1997;148(3):198\u2013204.","journal-title":"Ann Med Interne (Paris)"},{"issue":"11","key":"2415_CR35","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1681\/ASN.2019111197","volume":"31","author":"M Casal Moura","year":"2020","unstructured":"Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol. 2020;31(11):2688\u2013704.","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"2415_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/1756-185X.13483","volume":"22","author":"G Bornstein","year":"2019","unstructured":"Bornstein G, Ben-Zvi I, Furie N, Grossman C. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis. Int J Rheum Dis. 2019;22(5):940\u20135.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"2415_CR37","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s10067-016-3195-z","volume":"35","author":"BM C\u00f3rdova-S\u00e1nchez","year":"2016","unstructured":"C\u00f3rdova-S\u00e1nchez BM, Mej\u00eda-Vilet JM, Morales-Buenrostro LE, Loyola-Rodr\u00edguez G, Uribe-Uribe NO, Correa-Rotter R. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. Clin Rheumatol. 2016;35(7):1805\u201316.","journal-title":"Clin Rheumatol"},{"key":"2415_CR38","unstructured":"Natorska J, Z\u0105bczyk M, Siudut J, Krawiec P, Mastalerz L, Undas A. Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation. Clin Exp Rheumatol. 2017;35 Suppl 103(1):27\u201332."},{"issue":"2","key":"2415_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","volume":"19","author":"RI Hassan","year":"2017","unstructured":"Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep. 2017;19(2):6.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2415_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1189\/jlb.0104054","volume":"77","author":"JW Calderwood","year":"2005","unstructured":"Calderwood JW, Williams JM, Morgan MD, Nash GB, Savage CO. ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol. 2005;77(1):33\u201343.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"2415_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.transci.2019.04.006","volume":"58","author":"HP Pham","year":"2019","unstructured":"Pham HP, Staley EM, Schwartz J. Therapeutic plasma exchange - a brief review of indications, urgency, schedule, and technical aspects. Transfusion Apher Sci. 2019;58(3):237\u201346.","journal-title":"Transfusion Apher Sci"},{"issue":"11","key":"2415_CR42","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.1780381116","volume":"38","author":"L Guillevin","year":"1995","unstructured":"Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638\u201345.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2415_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/art.1780350214","volume":"35","author":"L Guillevin","year":"1992","unstructured":"Guillevin L, Fain O, Lhote F, Jarrousse B, Du Le Thi H, Bussel A, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective, randomized trial in 78 patients. Arthritis Rheum. 1992;35(2):208\u201315.","journal-title":"Arthritis Rheum"},{"key":"2415_CR44","doi-asserted-by":"crossref","unstructured":"Bala MM, Malecka-Massalska TJ, Koperny M, Zajac JF, Szczeklik W. Anti-cytokine targeted therapies for ANCA-associated vasculitis. Cochrane Database Syst Rev. 2010;1. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008333\/full.","DOI":"10.1002\/14651858.CD008333"},{"issue":"5 Pt 1","key":"2415_CR45","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7326\/0003-4819-89-5-660","volume":"89","author":"AS Fauci","year":"1978","unstructured":"Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978;89(5 Pt 1):660\u201376.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2415_CR46","first-page":"1","volume":"29","author":"WM Gl\u00f6ckner","year":"1988","unstructured":"Gl\u00f6ckner WM, Sieberth HG, Wichmann HE, Backes E, Bambauer R, Boesken WH, et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin Nephrol. 1988;29(1):1\u20138.","journal-title":"Clin Nephrol"},{"issue":"3","key":"2415_CR47","first-page":"587","volume":"6","author":"JM Mauri","year":"1985","unstructured":"Mauri JM, Gonzalez MT, Poveda R. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis. Plasma Ther Transfusion Technol. 1985;6(3):587\u201391.","journal-title":"Plasma Ther Transfusion Technol"},{"issue":"3","key":"2415_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0272-6386(12)80699-8","volume":"20","author":"E Cole","year":"1992","unstructured":"Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992;20(3):261\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2415_CR49","first-page":"263","volume":"337","author":"G Rifle","year":"1990","unstructured":"Rifle G, Dechelette E. Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group. Prog Clin Biol Res. 1990;337:263\u20137.","journal-title":"Prog Clin Biol Res"},{"key":"2415_CR50","first-page":"493","volume":"18","author":"G Rifle","year":"1981","unstructured":"Rifle G, Chalopin JM, Zech P, Deteix P, Ducret F, Vialtel P, et al. Treatment of idiopathic acute crescentic glomerulonephritis by immunodepression and plasma-exchanges. A prospective randomised study. Proc Eur Dial Transplant Assoc. 1981;18:493\u2013502.","journal-title":"Proc Eur Dial Transplant Assoc"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02415-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-021-02415-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02415-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T13:23:50Z","timestamp":1610630630000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02415-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2415"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02415-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"21 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}